Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Patients primary malignant peritoneal mesothelioma (MPM), without extra-abdominal disease,
that are not eligible (or willing) to undergo cytoreductive surgery (CRS) with hyperthermic
intraperitoneal chemotherapy (HIPEC) can be included in this study. Patients will be treated
with intraperitoneal (IP) chemotherapy (paclitaxel) in weekly cycles. The primary aim of this
study is to determine the maximum tolerable dose (MTD) of IP monotherapy with paclitaxel for
patients with MPM. The secondary aims are to assess safety and feasibility of this strategy,
and to study the pharmacokinetics of paclitaxel in this setting.